Posts tagged Farzin Farzaneh
Gene therapy ‘factory’ to save children
Gene therapy ‘factory’ to save children

A new “factory” that will produce benign viruses for Great Ormond Street Hospital is expected to accelerate the development of life-saving gene therapy drugs.

The facility, which is based in the hospital and operated by the biotech company ViroCell Biologics, will more than double Britain’s capacity to manufacture a key type of gene therapy.

Read More
In the NewsFlorence BuchananVirocell BiologicsGOSH, CDMO, Gene and cell therapies, viral vector, cell therapy, gene therapy, The Times, UK CDMO, Great Ormond Street Hospital, ViroCell, John W. Hadden II, Farzin Farzaneh, biotech, Dame Kate Bingham, John Hadden, Rhys Evans, SCID, severe combined immunodeficiency, Professor Claire Booth, leukaemia, spinal muscular atrophy, Leber congenital amaurosis, inherited diseases
Virocell and Great Ormond Street Hospital team up to tackle viral vector shortage
Virocell and Great Ormond Street Hospital team up to tackle viral vector shortage

ViroCell Biologics confirms a new agreement to address the worldwide viral vector market for clinical trials.

Read More
In the NewsFlorence BuchananCDMO, GOSH, Zayed Centre for Research, clean rooms, cell and gene therapies, 1L to 200L batch size, viral vectors, lentivirus vector, AAV vectors, CGT, gene therapy, cell therapy, Life Sciences Review, UK CDMO, ViroCell, Great Ormond Street Hospital, John W. Hadden II, Farzin Farzaneh, Matthew Shaw
ViroCell and Great Ormond Street Hospital for Children address viral vector manufacturing bottleneck
ViroCell and Great Ormond Street Hospital for Children address viral vector manufacturing bottleneck

As part of the partnership, ViroCell will more than double the UK’s lentivirus vector manufacturing capacity for clinical trials in 2022 and become the first UK CDMO to be able to deliver AAV vectors to the cell and gene therapy markets.

Read More
In the NewsFlorence BuchananCDMO, GOSH, Zayed Centre for Research, clean rooms, cell and gene therapies, 1L to 200L batch size, viral vectors, lentivirus vector, AAV vectors, CGT, gene therapy, cell therapy, Health Newest, UK CDMO, John W. Hadden II, Farzin Farzaneh
ViroCell Biologics and Great Ormond Street Hospital for Children Announce Partnership to Dislodge Gene and Cell Therapy “Logjam”
ViroCell Biologics and Great Ormond Street Hospital for Children Announce Partnership to Dislodge Gene and Cell Therapy “Logjam”

ViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, and Great Ormond Street Hospital for Children NHS Foundation Trust (“GOSH”), a world leading children’s hospital, have today announced a new partnership that will immediately address the global viral vector manufacturing bottleneck for clinical trials.

Read More
In the NewsFlorence BuchananCDMO, GOSH, Zayed Centre for Research, clean rooms, cell and gene therapies, 1L to 200L batch size, viral vectors, lentivirus vector, AAV vectors, CGT, gene therapy, cell therapy, Pharmiweb.com, UK CDMO, ViroCell, John W. Hadden II, Farzin Farzaneh, Matthew Shaw, Scientific Advisory Board
Partners aim to remove clinical trials bottleneck
Partners aim to remove clinical trials bottleneck

Life sciences firm ViroCell Biologics is working in partnership with Great Ormond Street Hospital (GOSH) to help alleviate a major barrier to progress in clinical trials.

Read More
In the NewsFlorence BuchananCDMO, GOSH, Zayed Centre for Research, clean rooms, cell and gene therapies, 1L to 200L batch size, viral vectors, lentivirus vector, AAV vectors, CGT, cell therapy, gene therapy, Health Tech World, UK CDMO, vector design, John W. Hadden II, Farzin Farzaneh
ViroCell Announces new Board appointments
ViroCell Announces new Board appointments

ViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, today announces the appointment of J. David Enloe, Jr. to its Board of Directors and Martin Pule, MD, PhD to its Scientific Advisory Board, both leaders in their respective fields.

Read More
In the NewsFlorence BuchananCDMO, ViroCell Board of Directors, Pharmiweb.com, UK CDMO, ViroCell, Recro Pharma, Board of Directors, Scientific Advisory Board, Dr. Martin Pule, J. David Enloe, John W. Hadden II, Farzin Farzaneh, gene therapy, cell therapy, CGT, viral vector, AAV vectors, lentivirus vectors, University College London
ViroCell Announces New Board Appointments
ViroCell Announces New Board Appointments

ViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, today announces the appointment of J. David Enloe, Jr. to its Board of Directors and Martin Pule, MD, PhD to its Scientific Advisory Board, both leaders in their respective fields.

Read More
In the NewsFlorence BuchananCDMO, ViroCell Board of Directors, Scientific Advisory Board, J. David Enloe, Martin Pule, Pharmtech Focus, ViroCell, Board of Directors, UK CDMO, gene therapy, cell therapy, CGT, Recro Pharma, Lonza, University College London, Autolus Therapeutics, AUTL, John W. Hadden II, Farzin Farzaneh, David Enloe, vector design, AAV vectors, lentivirus vectors
Tech News: ViroCell Biologics
Tech News: ViroCell Biologics

ViroCell Biologics, the UK’s first clinical trial-focused viral vector manufacturer, has officially launched.

It aims to be the supplier of choice for viral vectors and gene-modified cells, to academic and corporate clients, for translational cell and gene therapies going into clinical trials.

Read More
In the NewsFlorence BuchananCDMO, clinical trials, viral vectors, cell and gene therapies, The Biomedical Scientist, vector design, gene therapy, cell therapy, CGT, UK CDMO, Farzin Farzaneh, King's College London, viral vector
ViroCell released in the UK to make viral vectors
ViroCell released in the UK to make viral vectors

ViroCell will supply viral vectors and genetically modified cells to academic and corporate customers for translational cell and gene therapy entering clinical trials.

Read More
In the NewsFlorence BuchananCDMO, clinical trials, viral vectors, cell and gene therapies, EX Bulletin, UK CDMO, gene therapy, cell therapy, CGT, viral vector, vector design, AAV vectors, lentivirus vectors, ViroCell, John W. Hadden II, Farzin Farzaneh, Edmund Truell, Truell Conservation Foundation, King's College London
Global Roundup. Elsewhere across the globe: ViroCell Biologics
Global Roundup. Elsewhere across the globe: ViroCell Biologics

ViroCell Biologics – U.K.-based ViroCell launched with the goal to become the supplier of choice for viral vectors and gene-modified cells. Viral vectors are the primary delivery method for many innovative vaccines.

Read More
In the NewsFlorence BuchananCDMO, clinical trials, viral vectors, cell and gene therapies, BioSpace, UK CDMO, ViroCell, gene therapy, cell therapy, viral vector, vector design, AAV vectors, lentivirus vectors, Farzin Farzaneh
ViroCell Launched in the UK to Manufacture Viral Vectors
ViroCell Launched in the UK to Manufacture Viral Vectors

ViroCell will supply viral vectors and gene modified cells, to academic and corporate clients, for translational cell and gene therapies going into clinical trials.

Read More
In the NewsFlorence BuchananCDMO, clinical trials, viral vectors, cell and gene therapies, PharmTech.com, gene therapy, cell therapy, AAV vectors, lentivirus vectors, UK CDMO, Farzin Farzaneh, Truell Conservation Foundation, Edmund Truell, King's College London, vector design, CGT
First UK-based clinical trial focused viral vector manufacturer announces launch
First UK-based clinical trial focused viral vector manufacturer announces launch

ViroCell Biologics, the primary clinical trial focused viral vector manufacturer within the UK, has introduced its official launch, with the intention of turning into the ‘supplier of choice’ for viral vectors and gene modified cells.

Read More
In the NewsFlorence BuchananCDMO, clinical trials, viral vectors, cell and gene therapies, ViroCell, Farzin Farzaneh, Truell Conservation Foundation, John Hadden II, gene therapy, cell therapy, CGT, UK CDMO, UR ALL news, vector design, AAV vectors, lentivirus vectors
Introducing ViroCell Biologics. The UK’s first clinical trial focused viral vector manufacturer.
Introducing ViroCell Biologics. The UK’s first clinical trial focused viral vector manufacturer.

ViroCell Biologics, founded in the UK by a prolific academic viral vector manufacturing team, has officially launched. Viral vectors are the primary delivery method for innovative vaccines such as the Oxford/Astra Zeneca COVID vaccine, as well as enabling inputs for the manufacture of the rapidly growing Cell and Gene Therapy sector (CGT).

Read More
In the NewsFlorence BuchananCDMO, ViroCell, viral vector, viral vectors, AAV vectors, lentivirus vectors, gene therapy, cell therapy, CGT, Farzin Farzaneh, John W. Hadden II, Contract Pharma, UK CDMO, vector design
First UK-based clinical trial focused viral vector manufacturer announces launch
First UK-based clinical trial focused viral vector manufacturer announces launch

ViroCell Biologics, the first clinical trial focused viral vector manufacturer in the UK, has announced its official launch, with the aim of becoming the ‘supplier of choice’ for viral vectors and gene modified cells.

Read More
In the NewsFlorence BuchananCDMO, ViroCell, Truell Conservation Foundation, Farzin Farzaneh, John Hadden II, gene therapy, cell therapy, CGT, viral vector, viral vectors, vector design, AAV vectors, lentivirus vectors, UK CDMO, PharmaJobs